NFKB1 and cancer: Although the mechanisms of the anticancer effects of CDDOs are not fully understood, cancer cell differentiation, apoptosis and modulation of MAPK (Erk1/2), NF-κB, TGF-β/Smad and PPARγ signaling pathways contribute to the antitumor activity of CDDOs [17,18,19,20].